Isomorphic raised $5 billion with no drug in trials yet. Two pension funds agreed to buy into Cary Group. Fed minutes land at 2 p.m.

THE NUMBER

$5 billion.

That is what Isomorphic Labs raised in a Series C on Tuesday. None of its drugs has reached a clinical trial. Greenoaks and Sequoia Capital co-led the round. Its last raise, $2.1 billion, came in May. Isomorphic has not disclosed its valuation or named a drug candidate.

Backers paid for the engine before the first clinical result.

PREMIER FEATURE

7 Income Machines Built to Make You Rich

The 7 Stocks to Buy and Hold Forever aren’t just plays for the next quarter - they’re built to deliver for decades.

These are blue-chip companies with fortress balance sheets, elite dividend track records, and the staying power to outperform in bull and bear markets alike.

Some are Dividend Kings, others are on the path there, and all are proven wealth compounding machines.

Download the full list now - before it disappears behind the paywall.

THE SETUP
  • The 10-year Treasury yield closed Tuesday near 5.10%. Markets see a December rate hike as close to fully priced, UOB said. Minutes of the Fed's last meeting land at 2 p.m. Higher long rates make deal debt cost more.
  • Nvidia (NVDA) beat the midpoint of its own revenue forecast by $7.8 billion. It reported $115.8 billion for the quarter. It guided to $130 billion for this quarter, which has an extra week. The stock was up about 3% before dawn.
  • A judge hears the fight over a Getty Images equity committee at 10 a.m., per 9fin.
PMD Signal Tracker

FROM OUR PARTNERS

Who's on the Other Side of Your 0DTE Trade?

Every time you buy a same-day option, somebody sells it to you.

Most traders never stop to ask who that is, or why they're so happy to do it hours before the option expires.

My free report, The 0DTE Game Plan, shows you how the other side of the trade works, step by step, with your maximum loss set before you click.

Normally $29.97. Free today.

Download your copy now.

IN FOCUS

Two Pension Funds Are Buying Into Cary Group. CVC Gets a Full Exit.

CVC's eighth flagship fund agreed Tuesday to sell its stake of about 50% in Cary Group. The Swedish firm fixes car glass in 13 European countries. Two Canadian pension funds are expected to put in about €1 billion between them. They are CPP Investments and Ontario Teachers'. Nordic Capital, an owner since 2018, will cash out its old stake and reinvest.

The three will hold roughly equal stakes and share control. Terms were not disclosed. Bloomberg put the deal near €3 billion. It needs approval from regulators. Closing is expected in the first half of 2027.

CVC bought in during 2022. Cary had about 960 shops then, CVC said. It now has more than 1,800, after more than 100 deals. CVC put sales growth at 24% a year through its 2026 estimate.

Pensions Want a Seat at the Table, Not in a Fund

For buyout sellers, this is an exit to pension funds that want a say, not a slot in a fund. Their bet is that Cary keeps up its pace of buying shops. Our read is that big pensions will pay for proven platforms when they share control. The price, if disclosed at close, and whether the buying pace holds would test that read.

SIGNALS IN MOTION

SIGNAL 1: EQT Is Buying a Battery Pipeline. About a Quarter of It Is Under Contract.

EQT's transition infrastructure fund agreed to buy Flatiron Energy from Hull Street Energy. Flatiron builds large battery sites in the eastern U.S. Its pipeline totals 24 gigawatt-hours. Terms were not disclosed. The deal is expected to close in the fourth quarter.

About 6 gigawatt-hours are under long-term contracts. About 2 are being built. The rest still needs grid hookups, buyers and loans.

WHAT RESOLVES THIS

For infrastructure funds, most of what EQT is buying is not yet built. The contracted part should bring steadier cash once built, FM's analysis says. The rest carries development risk. How fast Flatiron turns its pipeline into signed contracts will show what EQT bought.

SIGNAL 2: Google Signed for Power From a Plant Not Yet Built. The Deal Reportedly Tops Its Cost.

Quaise Energy said Google signed to buy 50 megawatts from its geothermal site in Central Oregon. Deliveries could start as early as 2030. The companies did not disclose the price or length. The Wall Street Journal reported the deal is worth more than $500 million. Quaise told the Journal the project will cost about $350 million.

Quaise is private. It drills into far hotter rock than normal geothermal plants use. The Journal said its superhot approach has not been proven at commercial scale. No building loan tied to the contract has been reported. Alphabet (GOOGL) closed down 1.2% Tuesday, in a weak market.

WHAT RESOLVES THIS

For energy and venture investors, a signed buyer can make a new plant easier to finance. Quaise's backers have the most at stake, since a contract does not prove the rock will deliver. No drilling results from the site have been published. The first well results, and any loan tied to the contract, would show whether lenders agree.

SIGNAL 3: IDP Education Turned Down Blackstone a Third Time. Its Shares Trade Well Below the Offer.

IDP Education's board rejected Blackstone's third proposal, at A$3.00 a share in cash. The nonbinding offer values IDP at about A$834 million. Blackstone's first two bids, at A$2.30 and A$2.50, were turned down in September. The board said the offer "continues to substantially undervalue IDP." It will not open its books.

Changes to student-visa policy have hurt IDP's profit. The shares closed at A$2.42 on Wednesday, about 19% below the offer. Blackstone (BX) has not said whether it will raise its bid or walk away.

WHAT RESOLVES THIS

For buyout firms, this tests how low a bid can go when earnings are near a bottom. IDP holders have the gap to A$3.00 at stake. The gap may show doubt that a deal gets done at that price. A higher bid, or Blackstone taking its case to holders, would settle it.

PARTNER SPOTLIGHT

Live… From Inside Cybercab

I’m about to get into this Cybercab… and it’s going to take me to what Elon Musk called…

“The most epic AI project ever.”

Click here and come with me on this ride…

Because this is all part of Elon Musk’s $320 trillion masterplan.

WHAT MOST WILL MISS
  • Anthropic's IPO comes with a separate $26 billion private placement at the IPO price. Google and Nvidia each agreed to buy about $10 billion of it, the filing shows. Pricing is expected tonight, with trading Thursday on Nasdaq.
  • U.S. spot bitcoin funds lost $239.9 million Tuesday, per Farside data. Bitcoin was near $64,100 early Wednesday.
THE CROSSOVER

Private Market Trends Driving Public Market Moves

Private Money Paid Ahead of the Proof. Anthropic Is Expected to Price Tonight.

Private money paid for results that have not arrived. Isomorphic raised $5 billion before its first trial. EQT is buying a pipeline that is mostly unbuilt. Cary's new owners are betting its shop buying keeps going. Even Google, a public company, signed for power from a plant not yet built. IDP's board called Blackstone's bid "opportunistic in its timing." Public buyers face their own test tonight, when Anthropic is expected to price its IPO. Our read is that private money pays ahead when it picks the asset and the timing. Where Anthropic prices, and how it trades Thursday, will show if public buyers do the same.

On the calendar...

When

Event

Wed., Nov. 18

Getty equity committee hearing, 10 a.m., per 9fin; Fed minutes, 2 p.m.; Anthropic pricing expected

Thu., Nov. 19

Anthropic expected to begin trading; HVPE tender offer closes

T/W Dec. 8-9

Fed meeting

By Dec. 31

EQT/Flatiron expected close

Big Pharma Stopped Watching AI Drug Discovery. It Started Paying.

Sanofi has paid one AI biotech $144 million in upfront and milestone payments. Eli Lilly invested $40 million in another. Bristol Myers Squibb is putting a third company's AI co-scientist to work inside its own research organization.
The industry's biggest drugmakers used to watch this technology from the sidelines. Now they're customers.
We profiled the 5 companies leading AI drug development in a new FREE Special Report: AI Moves Into the Biotech Lab.
We'll text it straight to your phone.

Get the Free Report by Text →